Segall Bryant & Hamill LLC Makes New $1.85 Million Investment in CVS Health Co. (NYSE:CVS)

Segall Bryant & Hamill LLC purchased a new position in CVS Health Co. (NYSE:CVS - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 29,372 shares of the pharmacy operator's stock, valued at approximately $1,847,000.

A number of other large investors have also added to or reduced their stakes in the stock. West Family Investments Inc. boosted its holdings in shares of CVS Health by 13.6% in the third quarter. West Family Investments Inc. now owns 24,992 shares of the pharmacy operator's stock worth $1,571,000 after acquiring an additional 2,986 shares during the period. Second Half Financial Partners LLC purchased a new position in CVS Health during the 3rd quarter valued at about $359,000. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of CVS Health during the third quarter valued at about $3,888,000. Banque Cantonale Vaudoise lifted its holdings in shares of CVS Health by 1.7% in the third quarter. Banque Cantonale Vaudoise now owns 36,545 shares of the pharmacy operator's stock worth $2,298,000 after buying an additional 602 shares in the last quarter. Finally, Prospera Financial Services Inc increased its holdings in CVS Health by 5.8% during the 3rd quarter. Prospera Financial Services Inc now owns 34,555 shares of the pharmacy operator's stock worth $2,174,000 after acquiring an additional 1,908 shares during the period. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Trading Up 1.6 %

CVS stock traded up $0.91 on Friday, reaching $58.01. The company's stock had a trading volume of 11,153,900 shares, compared to its average volume of 12,620,673. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.59 and a current ratio of 0.80. The business has a fifty day simple moving average of $59.21 and a two-hundred day simple moving average of $58.61. The firm has a market cap of $73.00 billion, a PE ratio of 14.72, a PEG ratio of 0.96 and a beta of 0.55. CVS Health Co. has a 12-month low of $52.71 and a 12-month high of $83.25.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.01. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The company had revenue of $95.43 billion for the quarter, compared to analysts' expectations of $92.72 billion. During the same quarter in the previous year, the company earned $2.21 earnings per share. CVS Health's quarterly revenue was up 6.3% on a year-over-year basis. As a group, research analysts forecast that CVS Health Co. will post 5.43 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Monday, October 21st were paid a $0.665 dividend. The ex-dividend date of this dividend was Monday, October 21st. This represents a $2.66 annualized dividend and a dividend yield of 4.59%. CVS Health's payout ratio is 67.51%.

Analysts Set New Price Targets

A number of research firms have recently commented on CVS. Wells Fargo & Company upgraded shares of CVS Health from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $60.00 to $66.00 in a research report on Monday, November 18th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $62.00 price target on shares of CVS Health in a report on Tuesday, October 1st. UBS Group raised their target price on shares of CVS Health from $60.00 to $62.00 and gave the company a "neutral" rating in a research note on Thursday, November 7th. Truist Financial reissued a "buy" rating and issued a $67.00 target price (down previously from $76.00) on shares of CVS Health in a research note on Wednesday. Finally, Mizuho dropped their price target on CVS Health from $73.00 to $66.00 and set an "outperform" rating for the company in a research note on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $72.28.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.